Cargando…

GSK3β-dependent lysosome biogenesis: An effective pathway to mitigate renal fibrosis with LM49

Renal fibrosis is an incurable disorder characterised by an imbalance of the extracellular matrix (ECM) favouring excess production over degradation. The identification of actionable pathways and agents that promote ECM degradation to restore ECM homeostasis may help mitigate renal fibrosis. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Jinhong, Wei, Huizhi, Sun, Jian, Feng, Xiue, Zhang, Yuanlin, Yuan, Hongxia, Miao, Junqiu, Qi, Xiaoming, Qiao, Yuanbiao, Xiao, Baoguo, Li, Qingshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550195/
https://www.ncbi.nlm.nih.gov/pubmed/36225562
http://dx.doi.org/10.3389/fphar.2022.925489
_version_ 1784805826196668416
author Ren, Jinhong
Wei, Huizhi
Sun, Jian
Feng, Xiue
Zhang, Yuanlin
Yuan, Hongxia
Miao, Junqiu
Qi, Xiaoming
Qiao, Yuanbiao
Xiao, Baoguo
Li, Qingshan
author_facet Ren, Jinhong
Wei, Huizhi
Sun, Jian
Feng, Xiue
Zhang, Yuanlin
Yuan, Hongxia
Miao, Junqiu
Qi, Xiaoming
Qiao, Yuanbiao
Xiao, Baoguo
Li, Qingshan
author_sort Ren, Jinhong
collection PubMed
description Renal fibrosis is an incurable disorder characterised by an imbalance of the extracellular matrix (ECM) favouring excess production over degradation. The identification of actionable pathways and agents that promote ECM degradation to restore ECM homeostasis may help mitigate renal fibrosis. In this study, we identified 5,2′-dibromo-2,4′,5′-trihydroxydiphenylmethanone (LM49), a compound we previously synthesised, as a small-molecule inducer of ECM degradation. LM49 administration efficiently reduced ECM deposition in renal tissue of diabetic nephropathy rats and in transforming growth factor β-treated renal fibroblast cells. LM49 promoted the cytosol-to-nucleus translocation of transcription factor EB (TFEB) to increase lysosome biogenesis, leading to lysosome-based degradation of the ECM. TFEB-mediated lysosome biogenesis was induced by LM49 directly inhibiting the activity of glycogen synthase kinase 3β (GSK3β) rather than mammalian target of rapamycin complex 1. LM49 inhibited GSK3β kinase activity concentration-dependently via competing with ATP. Direct binding between LM49 and GSK3β was confirmed by the bio-layer interferometry assay, cellular thermal shift assay, and drug affinity responsive target stability. A molecular docking and molecular dynamic simulation revealed that LM49 occupied the ATP pocket of GSK3β, which was consistent with the kinase activity assay. In summary, LM49 enhances TFEB-mediated lysosome biogenesis by directly inhibiting GSK3β, leading to the degradation of the ECM by lysosomes. The enhancement of GSK3β-dependent lysosome biogenesis to rebalance the ECM may be a novel strategy to counteract renal fibrosis, and LM49 may be a viable clinical candidate for treating this disorder.
format Online
Article
Text
id pubmed-9550195
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95501952022-10-11 GSK3β-dependent lysosome biogenesis: An effective pathway to mitigate renal fibrosis with LM49 Ren, Jinhong Wei, Huizhi Sun, Jian Feng, Xiue Zhang, Yuanlin Yuan, Hongxia Miao, Junqiu Qi, Xiaoming Qiao, Yuanbiao Xiao, Baoguo Li, Qingshan Front Pharmacol Pharmacology Renal fibrosis is an incurable disorder characterised by an imbalance of the extracellular matrix (ECM) favouring excess production over degradation. The identification of actionable pathways and agents that promote ECM degradation to restore ECM homeostasis may help mitigate renal fibrosis. In this study, we identified 5,2′-dibromo-2,4′,5′-trihydroxydiphenylmethanone (LM49), a compound we previously synthesised, as a small-molecule inducer of ECM degradation. LM49 administration efficiently reduced ECM deposition in renal tissue of diabetic nephropathy rats and in transforming growth factor β-treated renal fibroblast cells. LM49 promoted the cytosol-to-nucleus translocation of transcription factor EB (TFEB) to increase lysosome biogenesis, leading to lysosome-based degradation of the ECM. TFEB-mediated lysosome biogenesis was induced by LM49 directly inhibiting the activity of glycogen synthase kinase 3β (GSK3β) rather than mammalian target of rapamycin complex 1. LM49 inhibited GSK3β kinase activity concentration-dependently via competing with ATP. Direct binding between LM49 and GSK3β was confirmed by the bio-layer interferometry assay, cellular thermal shift assay, and drug affinity responsive target stability. A molecular docking and molecular dynamic simulation revealed that LM49 occupied the ATP pocket of GSK3β, which was consistent with the kinase activity assay. In summary, LM49 enhances TFEB-mediated lysosome biogenesis by directly inhibiting GSK3β, leading to the degradation of the ECM by lysosomes. The enhancement of GSK3β-dependent lysosome biogenesis to rebalance the ECM may be a novel strategy to counteract renal fibrosis, and LM49 may be a viable clinical candidate for treating this disorder. Frontiers Media S.A. 2022-09-26 /pmc/articles/PMC9550195/ /pubmed/36225562 http://dx.doi.org/10.3389/fphar.2022.925489 Text en Copyright © 2022 Ren, Wei, Sun, Feng, Zhang, Yuan, Miao, Qi, Qiao, Xiao and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Ren, Jinhong
Wei, Huizhi
Sun, Jian
Feng, Xiue
Zhang, Yuanlin
Yuan, Hongxia
Miao, Junqiu
Qi, Xiaoming
Qiao, Yuanbiao
Xiao, Baoguo
Li, Qingshan
GSK3β-dependent lysosome biogenesis: An effective pathway to mitigate renal fibrosis with LM49
title GSK3β-dependent lysosome biogenesis: An effective pathway to mitigate renal fibrosis with LM49
title_full GSK3β-dependent lysosome biogenesis: An effective pathway to mitigate renal fibrosis with LM49
title_fullStr GSK3β-dependent lysosome biogenesis: An effective pathway to mitigate renal fibrosis with LM49
title_full_unstemmed GSK3β-dependent lysosome biogenesis: An effective pathway to mitigate renal fibrosis with LM49
title_short GSK3β-dependent lysosome biogenesis: An effective pathway to mitigate renal fibrosis with LM49
title_sort gsk3β-dependent lysosome biogenesis: an effective pathway to mitigate renal fibrosis with lm49
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550195/
https://www.ncbi.nlm.nih.gov/pubmed/36225562
http://dx.doi.org/10.3389/fphar.2022.925489
work_keys_str_mv AT renjinhong gsk3bdependentlysosomebiogenesisaneffectivepathwaytomitigaterenalfibrosiswithlm49
AT weihuizhi gsk3bdependentlysosomebiogenesisaneffectivepathwaytomitigaterenalfibrosiswithlm49
AT sunjian gsk3bdependentlysosomebiogenesisaneffectivepathwaytomitigaterenalfibrosiswithlm49
AT fengxiue gsk3bdependentlysosomebiogenesisaneffectivepathwaytomitigaterenalfibrosiswithlm49
AT zhangyuanlin gsk3bdependentlysosomebiogenesisaneffectivepathwaytomitigaterenalfibrosiswithlm49
AT yuanhongxia gsk3bdependentlysosomebiogenesisaneffectivepathwaytomitigaterenalfibrosiswithlm49
AT miaojunqiu gsk3bdependentlysosomebiogenesisaneffectivepathwaytomitigaterenalfibrosiswithlm49
AT qixiaoming gsk3bdependentlysosomebiogenesisaneffectivepathwaytomitigaterenalfibrosiswithlm49
AT qiaoyuanbiao gsk3bdependentlysosomebiogenesisaneffectivepathwaytomitigaterenalfibrosiswithlm49
AT xiaobaoguo gsk3bdependentlysosomebiogenesisaneffectivepathwaytomitigaterenalfibrosiswithlm49
AT liqingshan gsk3bdependentlysosomebiogenesisaneffectivepathwaytomitigaterenalfibrosiswithlm49